Strategic Lowering of LDL-Cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic...

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Ischemic stroke is a major global health concern, with dyslipidemia, specifically high low-density lipoprotein cholesterol (LDL-C), being a key modifiable risk factor.
• Statins are standard for stroke prevention, but optimal strategies for diverse patient groups and the role of newer agents require clarification.

Purpose of the Study:

• To provide a comprehensive overview of lipid-lowering therapies for post-stroke patients.
• To propose practical algorithms for individualized lipid management in stroke survivors.
• To bridge the gap between clinical evidence and practice for improved patient outcomes.

Main Methods:

• Narrative review of current literature on lipid-lowering therapies.
• Analysis of evidence for statins, PCSK9 inhibitors, bempedoic acid, and icosapent ethyl.
• Development of treatment algorithms based on patient profiles and lipid targets.

Main Results:

• Novel agents like PCSK9 inhibitors, bempedoic acid, and icosapent ethyl offer complementary roles to statins.
• Individualized treatment is essential, considering factors like statin intolerance, residual risk, and triglyceride levels.
• Evidence supports tailored lipid management for maximizing stroke prevention in high-risk populations.

Conclusions:

• Optimal lipid management post-stroke requires a personalized approach, integrating established and emerging therapies.
• Algorithms can guide clinicians in selecting appropriate treatments and lipid targets for stroke survivors.
• Individualized lipid-lowering strategies are key to reducing morbidity and mortality in this high-risk group.